TherapeuticsMD (TXMD) Competitors

TherapeuticsMD (NASDAQ:TXMD) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Which has higher valuation and earnings, TXMD or IFRX?

TherapeuticsMD has higher revenue and earnings than InflaRx.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$1.76M	7.56	-$2.18M	N/A	N/A
InflaRx	$180K	322.22	-$49.85M	-$0.82	-1.05

Which has more volatility and risk, TXMD or IFRX?

TherapeuticsMD has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Comparatively, InflaRx has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500.

Does the media prefer TXMD or IFRX?

In the previous week, InflaRx had 2 more articles in the media than TherapeuticsMD. MarketBeat recorded 3 mentions for InflaRx and 1 mentions for TherapeuticsMD. InflaRx's average media sentiment score of 0.40 beat TherapeuticsMD's score of 0.00 indicating that InflaRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TherapeuticsMD	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
InflaRx	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts recommend TXMD or IFRX?

InflaRx has a consensus target price of $6.60, suggesting a potential upside of 663.89%. Given InflaRx's stronger consensus rating and higher possible upside, analysts clearly believe InflaRx is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
InflaRx	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is TXMD or IFRX more profitable?

InflaRx has a net margin of 0.00% compared to TherapeuticsMD's net margin of -114.07%. TherapeuticsMD's return on equity of -7.86% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	-114.07%	-7.86%	-5.46%
InflaRx	N/A	-64.17%	-53.39%

Do institutionals and insiders hold more shares of TXMD or IFRX?

30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 42.4% of InflaRx shares are owned by institutional investors. 2.3% of TherapeuticsMD shares are owned by insiders. Comparatively, 16.3% of InflaRx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

InflaRx beats TherapeuticsMD on 10 of the 14 factors compared between the two stocks.